Daniel Ulbrich-Gebauer
A5010707939- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Genetics, Bioinformatics, and Biomedical Research
- Esophageal Cancer Research and Treatment
- Cancer Cells and Metastasis
LVR-Klinik für Orthopädie Viersen
2017-2024
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. all, 142 BCs were investigated using PAM50-based test Prosigna® in a prospective multicentric study. 119/142 cases, molecular subtyping was compared with local and two central (C1 C6) molecular-like subtypes relying on both immunohistochemistry (IHC; HRs, HER2, Ki-67) IHC + tumor grade (IHC+G) subtyping....
590 Background: pCR successfully identified candidates for (chemotherapy) de-escalation in the ADAPT HER2+ trial program. Here, we report biomarker analysis single arm, hypothesis-generating Keyriched-1 (NCT03988036) HER2-E eBC treated with pembrolizumab and dual HER2 blockade. The rationale is based on high efficacy of anti-HER2 agents potentially immunogenicity immune checkpoint protein expression eBC. Methods: 48 patients 2+ (ISH+) or 3+ (stage I-III) subtype received (200 mg),...
Abstract Purpose: To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452). Experimental Design: Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, n = 92) or P+T+paclitaxel (n 42). Gene expression analyzed baseline biopsies using NanoString Breast Cancer 360 panel 117); on-treatment...
Abstract Background In unselected HER2+ early breast cancer (EBC), de-escalated chemotherapy-free neoadjuvant therapy (NAT) with dual HER2-blockade induces pCR rates of only 20%-40%. order to achieve by comparable those achieved chemotherapy-based regimens, patient selection and more effective regimens are thus key. KEYRICHED-1 (NCT03988036), a single-arm phase 2 study, is the first trial investigate NAT HER2 blockade pembrolizumab in HER2-enriched EBC. translational subproject, we analyzed...
<p>CONSORT diagram</p>
<div>AbstractPurpose:<p>To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> trial (NCT01817452).</p>Experimental Design:<p>Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, <i>n</i> = 92) or P+T+paclitaxel...
<p>Supplementary Figure 2 shows association between RNA signatures and ypT0/is ypN0</p>
<p>Supplementary Figure 3 shows association between RNA signatures and overall survival</p>
<p>Supplementary Figure 2 shows association between RNA signatures and ypT0/is ypN0</p>
<p>CONSORT diagram</p>
<div>AbstractPurpose:<p>To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> trial (NCT01817452).</p>Experimental Design:<p>Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, <i>n</i> = 92) or P+T+paclitaxel...
<p>Supplementary Figure 3 shows association between RNA signatures and overall survival</p>
Eine Entscheidung für Systemtherapie bei Brustkrebspatientinnen hängt von prognostischen und prädiktiven klinisch-pathologischen Faktoren wie Tumorgröße, Nodalstatus, Hormonrezeptor- (HR) HER2-Expression entsprechendem immunhistochemischen (IHC) Subtyp ab. In HR-positiven/HER2-negativen Fällen mit intermediärem Risiko können Multigenexpressionstests die adjuvante Chemotherapie unterstützen.